Ontario Public Drug Programs
Executive Officer Communications
| Date | Title |
|---|---|
| 2017 | |
| September 21 | Notice from the Executive Officer: Notice from the Executive Officer: Promoting Compliance with the Existing Limited Use Criteria for the Fentanyl Transdermal Patch English | French – Frequently Asked Questions English | French |
| September 21 | Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Support the Homes for Special Care Modernization Initiative English | French |
| September 1 | Notice from the Executive Officer: Amendments to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management English | French |
| September 1 | Notice from the Executive Officer: Amendment to Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare English | French |
| August 23 | Notice from the Executive Officer: Notice from the Executive Officer: Thyroid (Desiccated Thyroid) Delisting English | French |
| August 3 | Notice from the Executive Officer: Funding of Mifepristone/Misoprostol (Mifegymiso)
English | French – Frequently Asked Questions for Health Care Providers (updated September 11, 2017) English | French – Frequently Asked Questions for Patients English | French |
| August 1 | Notice from the Executive Officer: Funding of filgrastim under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| July 21 | Notice from the Executive Officer: Funding of Brenzys (etanercept) under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| July 11 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Create and Implement OHIP+: Children and Youth Pharmacare Program English | French |
| July 7 | Notice from the Executive Officer: Ontario Drug Benefit Act, Legislative amendments to recognize the role of Nurse Practitioners in requesting Exceptional Access Program products and prescribing Listed Substances (Bill 87)
English | French – Frequently Asked Questions for Health Care Providers English | French |
| June 29 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 made under the Ontario Drug Benefit Act to Strengthen Pharmacy Payment Management English | French |
| March 16 | Notice from the Executive Officer: Pan-Canadian Select Molecule Price Initiative for Generic Drugs English | French |
| February 21 | Notice from the Executive Officer: Funding of Hepatitis C drug products under the Ontario Drug Benefit Program English | French – Frequently Asked Questions for Health Care Providers English | French – Frequently Asked Questions for Patients English | French |
| January 27 | Notice from the Executive Officer: Updated Reminder Regarding Delisting of High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program English | French |
| 2016 | |
| December 21 | Notice from the Executive Officer: Funding of Grastofil (filgrastim) under the Ontario Drug Benefit program English | French – Frequently Asked Questions English | French |
| December 1 | Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| November 30 | Notice from the Executive Officer: Update Regarding Palliative Care Access to High-Strength Long-Acting Opioids under the Ontario Drug Benefit (ODB) Program English | French |
| October 24 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccines for 2016-2017 Season and Claims Submission using the Health Network System English | French – Frequently Asked Questions English | French |
| October 07 | Notice from the Executive Officer: Application of Generic Substitution to the Exceptional Access Program English | French – Frequently Asked Questions for Patients English | French – Frequently Asked Questions for Pharmacists English | French – Frequently Asked Questions for Physicians English | French |
| September 26 | Notice from the Executive Officer: Regulation amendments to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products English | French |
| September 16 | Notice from the Executive Officer: Regulation to support the Safeguarding our Communities Act, 2015 (Patch for Patch Return Program) English | French – Frequently Asked Questions for Prescribers and Pharmacists English | French – Frequently Asked Questions for Patients English | French |
| September 16 | Notice from the Executive Officer: Drug Submission – Ontario Guidelines for Drug Submission and Evaluation 2016 English | French |
| September 02 | Notice from the Executive Officer: Changes in the Way Social Assistance Clients Access Drug Coverage – Updated Drug Eligibility Card Pharmacy Information Sheet For Social Assistance Clients – Drug Eligibility Card Client Information Sheet |
| August 17 | Notice from the Executive Officer: Reminder - Ontario Naloxone Program for Pharmacies (ONPP) Notice from the Executive Officer: Ontario Naloxone Program for Pharmacies (ONPP) – Frequently Asked Questions for Pharmacists |
| August 15 | Notice from the Executive Officer: Reimbursement and Claims Submissions using the Health Network System relating to Drugs for Medical Assistance in Dying English | French – Frequently Asked Questions for Pharmacists English | French |
| July 20 | Notice from the Executive Officer: Changes to the Ontario Drug Benefit (ODB) Program Funding of Opioid Medications English | French – Frequently Asked Questions for Pharmacists English | French |
| July 4 | Notice from the Executive Officer: MedsCheck Program Enhancements English | French |
| June 10 | Notice from the Executive Officer: Health Network System (HNS) Changes to Support the Maximizing Quantity Dispensed for Chronic-Use Medications Initiative English | French – Frequently Asked Questions English | French |
| June 1 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act to optimize appropriate access to unlisted, non-Formulary drug products and further streamline submission requirements for generic drug products English | French |
| June 1 | Notice from the Executive Officer: Proposed Regulation under the Safeguarding our Communities Act (Patch for Patch Return Policy) English | French |
| April 15 | Notice from the Executive Officer: Regulation Amendments to Expand Access to the Seniors’ Co-Payment Program under the Ontario Drug Benefit (ODB) Program English | French |
| March 22 | Executive Officer Notice Drug Submission – Information Bulletin English | French |
| March 15 | Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs English | French |
| March 11 | Notice from the Executive Officer: Funding of Inflectra under the Ontario Drug Benefit Program English | French – Frequently Asked Questions English | French |
| February 29 | Notice from the Executive Officer:Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act to update cost-sharing arrangements for non-low income seniors under the Ontario Drug Benefit (ODB) program English | French |
| 2015 | |
| November 23 | Notice from the Executive Officer: New Blood Glucose Test Strip Reimbursement Policy English | French |
| November 13 | Notice from the Executive Officer: Claims submission for prescriptions with drug costs over $10,000 English | French – Frequently Asked Questions English | French |
| October 13 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2015-2016 Season and Claims Submission using the Health Network System |
| September 18 | Notice from the Executive Officer: Regulation Amendments to Streamline Submission Requirements for Certain Generic Products seeking Interchangeability Designations on the Ontario Drug Benefit Formulary English | French |
| September 18 | Notice from the Executive Officer: Regulation Amendments to Support Sustainability and Access for the Ontario Public Drug Programs English | French |
| September 18 | Notice from the Executive Officer: Supporting Sustainability and Access for the Ontario Drug Benefit Program English | French – Questions & Answers for Pharmacists English | French – Questions & Answers for Physicians English | French – Questions & Answers for Patients English | French – Chronic-use Medications List by Generic Name English |
| July 23 | Notice from the Executive Officer: Proposal to amend Ontario Regulation 201/96 under the Ontario Drug Benefit Act and Regulation 935 under the Drug Interchangeability and Dispensing Fee Act English | French – Questions & Answers for Patients English | French |
| May 20 | Notice from the Executive Officer: Tiered Generic Pricing Framework English | French |
| March 10 | Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs English | French |
| 2014 | |
| November 5, 2014 | Notice from the Executive Officer: Proposed Regulation Amendments to Establish a Pricing Framework for Certain Generic Products on the Ontario Drug Benefit (ODB) Formulary English | French |
| October 10 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2014-2015 Season and Claims Submission using the Health Network System English | French – Frequently Asked Questions updated November 21, 2014 English | French |
| July 17 | Notice from the Executive Officer: Methadone Maintenance Treatment - Extended Transition Period English | French |
| June 26 | Notice from the Executive Officer: Methadone Maintenance Treatment. – Frequently Asked Questions for Pharmacists # 2 English | French |
| June 20 | Notice from the Executive Officer: Methadone Maintenance Treatment Reimbursement Policy, 2014, effective June 26, 2014 English | French Changes to Methadone Maintenance Treatment : Frequently Asked Questions for Patients English | French Changes to Methadone Maintenance Treatment : Frequently Asked Questions for Pharmacists English | French Changes to Methadone Maintenance Treatment : Frequently Asked Questions for Physicians English | French |
| March 11 | Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2014 [PDF] |
| March 10 | Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs [PDF] |
| 2013 | |
| November 28 | Notice from the Executive Officer: Edition 42 of the Ontario Drug Benefit Formulary [PDF] |
| November 26 | Notice from the Executive Officer: Accuracy in Claims Submissions [PDF] |
| October 4 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine for 2013-2014 Season and Claims Submission using the Health Network System english | french |
| September 17 | Blood Glucose Test Strip Reimbursement Update [PDF] |
| July 11 | Notice to Pharmacies - Contacting the ODB Help Desk [PDF] |
| July 8 | Notice from the Executive Officer: Blood Glucose Test Strip Reimbursement Policy [PDF] english | french |
| June 11 | Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| March 7 | Notice from the Executive Officer: Reminder of the Upcoming Changes for April 1, 2013 |
| March 4 | Notice from the Executive Officer: Pan-Canadian Competitive Value Price Initiative for Generic Drugs |
| February 20 | Important Notice from the Executive Officer: Proper Submission of Prescriber Identification to the Health Network System (HNS) and Narcotics Monitoring System (NMS) [PDF] |
| February 13 | Notice from the Executive Officer: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| February 4 | Notice from the Executive Officer: FINAL Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet – OxyNEO [PDF] |
| January 24 | Notice from the Executive Officer: New Regulatory Requirements for Long-Acting Oxycodone Drug Products [PDF] |
| January 15 | Notice from the Executive Officer: Assignment of ON Numbers to Health Network System/Ontario Drug Benefit Accounts |
| 2012 | |
| December 20 | Notice from the Executive Officer: Expanded Scope of Practice and Accuracy in Claims Submission [PDF] |
| December 12 | Delisting of Aliskiren (Rasilez®) from the ODB Formulary - Questions & Answers |
| November 28 | Important notice regarding the prescribing and dispensing of Oxycodone CR. english | french |
| November 23 | Proposed Regulation Amendments to Set Additional Conditions for Submission Requirements of Long-Acting Oxycodone Drug Products english | french |
| October 10 | Notice to Pharmacies – Contacting the Help Desk [PDF] |
| October 9 | Notice from the Executive Officer: Pharmacist Administration of Publicly Funded Influenza Vaccine and Claims Submission using the Health Network System; 2012-2013 Influenza Season - Fact Sheet - Q & As |
| October 4 | Notice from the Executive Officer: Important Reminder Regarding the Funding Status of Oxycodone Controlled Release Tablet - OxyNEO [PDF] |
| September 27 | Notice from the Executive Officer: Changes to the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program |
| September 24 | Important Notice from the Executive Officer: Proper Submissions to the Narcotics Monitoring System (NMS) [PDF] |
| August 20 | Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers [Excel] |
| August 15 | Proposed Regulation Amendment to Reduce the Transition Fee Payments under the Ontario Drug Benefit (ODB) Program |
| May 8 | Important Notice from the Executive Officer: Submission of Monitored Drug Information to the Narcotics Monitoring System |
| April 12 | Notice from the Executive officer. Re: Implementation of the Narcotics Monitoring System (NMS) english | french |
| March 16 | Notice from the Executive Officer. Re: Upcoming Changes for April 1, 2012 |
| February 27 | Notice from the Executive Officer. Re: Pharmaceutical Opinion Program |
| February 17 | Notice from the Executive Officer: RE: Important Notice Regarding Change in Funding Status of Oxycodone Controlled Release Tablet – (Discontinuation of OxyContin and Introduction of OxyNEO) english | french |
| February 6 | Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| 2011 | |
| December 6 | Notice from the Executive officer. Re: Prescriber ID Requirements for Claims Submitted on the Health Network System (HNS) |
| November 30 | Notice from the Executive Officer. Re: Additional Clarification Regarding the Narcotics Legislation |
| October 27 | Notice from the Executive Officer. Re: Additional Questions on the Narcotics Legislation english | french |
| October 14 | Important Notice to Health Care Providers on the New Requirements under the Narcotics Safety and Awareness Act, 2010 |
| October 14 | Public Notice Regarding the Ministry of Health and Long-Term Care's ("ministry") Collection, Use and Disclosure of Information under the Narcotics Safety and Awareness Act, 2010 english | french |
| September 9 | Suspension of Ontario Drug Benefit (ODB) Billing Accounts |
| August 31 | Notice from the Executive Officer. Re: MedsCheck Program Standardization and system Requirements |
| August 31 | Notice from the Executive Officer. Re: Pharmaceutical Opinion Program |
| August 29 | Notice from the Executive Officer. Re: Pharmacy Smoking Cessation Program |
| August 22 | Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for September 1, 2011 |
| July 28 | Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| June 10 | Notice from the Executive Officer. Re: Extension of Transition Fee Payments and Conditions for Payment of Dispensing Fees for Remote Dispensing Location under the Ontario Public Drug Programs |
| May 24 | Clarification to the Notice from the Executive Officer. Re: Lucentis – Change in Status to Limited Use (April 1, 2011) |
| April 7 | Notice from the Executive Officer. Re: New Regulation under the Optometry Act, 1991 |
| April 4 | Notice from the Executive Officer. Re: Request for Qualification (RFQ) for Acquirer Host Network Services |
| April 1 | Notice from the Executive Officer. Re: EAP criteria change for rosiglitazone (Avandia) |
| April 1 | Notice from the Executive Officer. Re: Lucentis - Change in Status to Limited Use |
| March 29 | Notice from the Executive Officer. Re: Implementation of the first stage of expanded services |
| March 23 | Notice from the Executive Officer. Re: Expanding Professional Pharmacy Services for April 1, 2011 |
| March 23 | Notice from the Executive Officer. Re: Increase in Dispensing Fees, Effective April 1, 2011 |
| March 18 | Notice from the Executive Officer. Re: New Regulation under the Drug and Pharmacies Regulation Act (DPRA) |
| February 28 | Notice from the Executive Officer. Re: Professional Allowances Reporting Template for Drug Manufacturers |
| February 09 | Notice from the Executive Officer. Re: Narcotics Monitoring System Questions and Answers |
| 2010 | |
| December 6 | Notice from the Executive Officer. Re: Formulary Listing for Enalapril Maleate |
| October 19 | Q & As for Change in Listing Status for Gabapentin |
| September 30 | Notice from the Executive Officer. Re: Pharmacy ONE Mail System Registration - Reminder Notice |
| September 8 | Notice from the Executive Officer. RE: MedsCheck Program Expanded Services Launched September 13, 2010 |
| August 26 | Notice from the Executive Officer: Change in Status to Limited Use (Humira and Enbrel) & New Limited Use Listing (Stelara) - Q & As for Change in Listing Status for Humira, Enbrel, and Stelara |
| August 23 | Notice from the Executive Officer. RE: Expanding Professional Pharmacy Services Working Group |
| July 13 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| June 08 | Notice from Ontario Public Drug Programs Re: Clarification of Digoxin Listings |
| January 25 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| 2009 | |
| July 17 | Policy to Acquire Medications for Treatment of Tuberculosis - Dear Pharmacist Letter. Communiqué from the Public Health Division, MOHLTC |
| July 15 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| May 6 | Notice from the Executive Officer: Change of Funding Status Rosiglitazone (Avandia®) and Pioglitazone (Actos® and Generics) - Q&As for TZD Funding Status Change |
| May 6 | Notice from the Executive Officer: Expanded Limited Use Criteria for Clopidogrel (Plavix) - Q&As for Clopidogrel Expanded LU Criteria |
| March 3 | Notice from the Executive Officer - MedsCheck Adjustment Payment to Pharmacies Ending on April 1, 2009 |
| February 23 | Notice from the Executive Officer: Ongoing Transparency Initiative: Public Posting of Drug Submission Status - Updates |
| February 4 | Notice from the Executive Officer: Reminder – Professional Allowance Reporting: July 1, 2008 to December 31, 2008 |
| January 13 | Notice from the Executive Officer: Academic Detailing Program - Q&As for Academic Detailing Program |
| 2008 | |
| December 19 | Notice from the Executive Officer: Health Network System (HNS) Enhancements to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program |
| December 17 | Notice from the Executive Officer: Renewal of the Health Network System (HNS) Subscription Agreement |
| December 1 | Notice from the Executive Officer: Enhancements to Health Network System to Support the Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program |
| December 1 | Notice from the Executive Officer: Announcement of Changes to the Formulary respecting Enalapril Maleate |
| November 17 | Notice from the Executive Officer: Telephone Request Service for Exceptional Access Program - Q&As for External Stakeholders |
| October 29 | Executive Officer Notice: Completing the New Health Network System (HNS) Agreement |
| October 27 | Executive Officer Notice: Price Increase Requests |
| October 20 | Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement |
| October 3 | Notice from the Executive Officer: Public Consultation to Review the definition of Professional Allowance and the Codes of Conduct |
| October 2 | Notice from the Executive Officer: Notice of Termination and Replacement of Agreement: Ontario Public Drug Programs Subscription Agreement |
| September 30 | Notice From Executive Officer: Implementation Plan To Review The Definition Of Professional Allowance And The Code Of Conduct |
| September 19 | Notice from the Executive Officer: Notice Of Cancellation Of Call For Application For Ranitidine Hydrochloride |
| August 26 | Notice from the Executive Officer: Drug Submissions Requirement - Revised Letter of Consent |
| August 22 | Notice from the Executive Officer Reminder - Professional Allowance Reporting |
| August 5 | Notice from the Executive Officer: Claims for ZANTAC® under the Ontario Drug Benefit Program |
| July 28 | Conditions for Payment of Dispensing Fees under the Ontario Drug Benefit (ODB) Program - Questions and Answers |
| July 18 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| July 16 | Notice from the Executive Officer: Competitive Agreements Q&As |
| July 8 | Notice from the Executive Officer: Ontario Public Drug Programs Competitive Agreement - Briefing for Stakeholders |
| June 4 | Notice from the Executive Officer: Manufacturer Review of Transparency Bulletin |
| May 29 | Notice from the Executive Officer: Pricing of Products Reimbursed Under the Exceptional Access Program (EAP) |
| May 16 | Notice from Executive Officer |
| May 16 | Notice from Executive Officer: Limited Use (LU) Process Changes |
| May 13 | Notice from Executive Officer: Ongoing Transparency Initiative - Public Posting of Drug Submission Status. |
| April 17 | Notice from the Executive Officer: Lucentis Questions and Answers |
| April 15 | Recruitment for Pharmacy Council Members, letter from the Executive Officer |
| March 6 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| January 30 | 2008 BBS Notice from the Executive Officer: MedsCheck, Adjustment Payment to Pharmacies - a Reminder |
| 2007 | |
| November 15 | Notice from the Executive Officer, BBS Introducing the "Follow-up" MedsCheck, effective November 30, 2007 |
| November 15 | Recruitment for Pharmacy Council Members, letter from the Executive Officer |
| November 13 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| October 19 | Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| October 1 | Notice to Manufacturers Submission Requirements for Generic Drug Products |
| October 4 |
(BBS Nº.7079) Notice from the Executive Officer: Lead Time Between the Formulary Update and Effective Date |
| September 14 | (BBS Nº.7071) Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| July | Letter to Pharmacists from the Executive Officer: MedsCheck Update |
| July 13 | Notice to Pharmacists: MedsCheck Update |
| May 29 | (BBS Nº.7029) MedsCheck Update |
| May 8 | (BBS Nº.7025) Notice to Pharmacists from Executive Officer: Follow up to April 5, 2007 Notice |
| April 1 | Letter to Pharmacists from the Executive Officer: MedsCheck |
| February 21 | (BBS Nº.7009) Notice from the Executive Officer: Reporting Framework for Professional Allowances |
| 2006 | |
| December 18 | (BBS Nº.6086) Notice from the Executive Officer: Amending Regulations under ODBA and DIDFA |
| September 28 | Notice to Pharmacists: Regulation Changes made to the Ontario Drug Benefit Act (ODBA) and the Drug Interchangeability and Dispensing Fee Act (DIDFA) |
| April 13 | (BBS Nº.6029) Notice to Pharmacists: Bill 102, Transparent Drug System for Patients Act |
Public Information
